Marviol (Desogestrel, Ethinylestradiol)

The two hormones work together to suppress the hypothalamic‑pituitary‑ovarian axis, reducing LH and FSH release, which blocks ovulation. Ethinylestradiol stabilises the endometrial lining, while desogestrel thickens cervical mucus, creating an environment that hinders sperm penetration and fertilisation.

The dosing regimen for Marviol is determined by the prescribing clinician based on the product’s approved label and the patient’s individual health profile. Typically, it is taken once daily at the same time for a 21‑day active phase followed by a hormone‑free interval, but exact instructions must come from a qualified prescriber.

Marviol is contraindicated during pregnancy because it is intended to prevent conception. If pregnancy occurs, the product should be discontinued. Limited data are available for breastfeeding; however, combined oral contraceptives are generally considered compatible with lactation, though clinicians may advise based on individual risk‑benefit assessment.

To request Marviol, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Marviol contains desogestrel and ethinylestradiol, a combination known for a lower androgenic profile and a reduced risk of certain side effects such as acne compared with older progestins. Its efficacy in preventing pregnancy is comparable to other approved combined pills, while its side‑effect profile may be more favourable for some users.

Marviol tablets should be stored at room temperature, below 25 °C (77 °F). Keep them in the original blister pack, protect from moisture, direct sunlight and excessive heat to maintain potency throughout the shelf life.

Marviol is taken orally with water, preferably at the same time each day. A typical cycle consists of 21 consecutive active tablets followed by a 7‑day hormone‑free interval during which withdrawal bleeding occurs. Patients should follow the specific schedule provided by their healthcare professional.

The most serious risks include venous thromboembolism, arterial thrombosis (such as heart attack or stroke), severe hypertension, and rare cases of liver dysfunction. Patients should be educated to seek immediate medical attention for symptoms like unexplained leg pain, chest pain, severe headache, or visual changes.

Marviol is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or those who are pregnant. It should also be avoided by smokers over 35 years of age and by individuals taking medications that significantly reduce its effectiveness.